Pfizer ends clinical trial
Pfizer Inc. has ended a Phase III clinical trial of tremelimumab in patients with advanced melanoma after a review of interim data showed that the drug was not better than standard chemotherapy.
pSivida has received its first quarterly payment of $500,000 from Pfizer as specified by the terms of an exclusive worldwide collaborative research and license agreement signed by the two companies in April, pSivida announced in a press release.